Skip to main content

Adaptive Two-Stage Designs for Single-Arm Phase IIA Cancer Clinical Trials

Buy Article:

$48.00 plus tax (Refund Policy)

Abstract:

Summary. 

The main purpose of a phase IIA trial of a new anticancer therapy is to determine whether the therapy has sufficient promise against a specific type of tumor to warrant its further development. The therapy will be rejected for further investigation if the true response rate is less than some uninteresting level and the test of hypothesis is powered at a specific target response rate. Two-stage designs are commonly used for this situation. However, in many situations investigators often express concern about uncertainty in targeting the alternative hypothesis to study power at the planning stage. In this article, motivated by a real example, we propose a strategy for adaptive two-stage designs that will use the information at the first stage of the study to either reject the therapy or continue testing with either an optimistic or a skeptic target response rate, while the type I error rate is controlled. We also introduce new optimal criteria to reduce the expected total sample size.

Keywords: Phase IIA cancer trials; Sample size; Two-stage designs

Document Type: Research Article

DOI: http://dx.doi.org/10.1111/j.0006-341X.2004.00193.x

Publication date: June 1, 2004

bpl/biom/2004/00000060/00000002/art00021
dcterms_title,dcterms_description,pub_keyword
6
5
20
40
5

Access Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content
Cookie Policy
X
Cookie Policy
ingentaconnect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more